2 weeks Ago By ABMN Staff
American Century Companies Inc. increased its holdings in Tyra Biosciences, Inc. ( NASDAQ:TYRA – Free Report ) by 582.
9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 170,283 shares of the company’s stock after purchasing an additional 145,346 shares during the quarter. American Century Companies Inc.
’s holdings in Tyra Biosciences were worth $2,723,000 at the end of the most recent reporting period. A number of other large investors also recently bought and sold shares of the business. Rhumbline Advisers raised its holdings in Tyra Biosciences by 12.
3% in the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock worth $377,000 after purchasing an additional 2,574 shares during the period. Bank of New York Mellon Corp raised its holdings in Tyra Biosciences by 32.
8% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock worth $929,000 after purchasing an additional 14,352 shares during the period. RA Capital Management L.
P. increased its stake in Tyra Biosciences by 43.9% during the 1st quarter.
RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock worth $170,832,000 after buying an additional 3,180,155 shares in the last quarter.
Kynam Capital Management LP increased its stake in Tyra Biosciences by 51.4% during the 1st quarter. Kynam Capital Management LP now owns 515,190 shares of the company’s stock worth $8,449,000 after buying an additional 175,000 shares in the last quarter.
Finally, BVF Inc. IL increased its stake in Tyra Biosciences by 70.1% during the 1st quarter.
BVF Inc. IL now owns 4,661,194 shares of the company’s stock worth $76,444,000 after buying an additional 1,921,599 shares in the last quarter. Institutional investors and hedge funds own 84.
14% of the company’s stock. Tyra Biosciences Price Performance TYRA stock opened at $23.34 on Friday.
The business has a 50 day simple moving average of $21.62 and a 200-day simple moving average of $18.86.
The firm has a market capitalization of $1.23 billion, a PE ratio of -13.89 and a beta of 1.
01. Tyra Biosciences, Inc. has a 1 year low of $10.
38 and a 1 year high of $25.14. Insider Buying and Selling In related news, CEO Todd Harris sold 10,092 shares of the stock in a transaction that occurred on Monday, September 23rd.
The stock was sold at an average price of $24.13, for a total value of $243,519.96.
Following the completion of the transaction, the chief executive officer now directly owns 1,479,528 shares in the company, valued at $35,701,010.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink .
Over the last three months, insiders sold 16,390 shares of company stock worth $396,444. Company insiders own 15.40% of the company’s stock.
Wall Street Analysts Forecast Growth Several research firms have commented on TYRA. Piper Sandler began coverage on Tyra Biosciences in a research note on Thursday, August 15th. They set an “overweight” rating and a $33.
00 price objective for the company. Wedbush reiterated an “outperform” rating and set a $28.00 price objective on shares of Tyra Biosciences in a research note on Thursday, August 8th.
HC Wainwright reiterated a “buy” rating and set a $23.00 price objective on shares of Tyra Biosciences in a research note on Wednesday, July 3rd. Finally, Oppenheimer boosted their price objective on Tyra Biosciences from $25.
00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, September 19th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock.
According to MarketBeat.com, Tyra Biosciences presently has an average rating of “Moderate Buy” and an average target price of $26.40.
View Our Latest Analysis on TYRA Tyra Biosciences Company Profile ( Free Report ) Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. See Also Want to see what other hedge funds are holding TYRA? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Tyra Biosciences, Inc. ( NASDAQ:TYRA – Free Report ). Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.
com's FREE daily email newsletter ..
